Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • AAP Policy
    • Topic/Program Collections
    • Policy
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effect on Pediatric Health
    • More Collections...
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Alerts
    • Table of Contents
    • Insights
  • AAP Career Center
  • Subscribe
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • AAP Policy
    • Topic/Program Collections
    • Policy
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effect on Pediatric Health
    • More Collections...
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Alerts
    • Table of Contents
    • Insights
  • AAP Career Center
  • Subscribe
NEWS AND FEATURES

Routine HPV vaccination recommended for all children at 11-12 years

Rodney E. Willoughby
AAP News March 2012, 33 (3) 16; DOI: https://doi.org/10.1542/aapnews.2012333-16
Rodney E. Willoughby Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • Comments
Loading
Download PDF
  • Copyright © 2012 by the American Academy of Pediatrics


Embedded Image

The Academy is recommending that both males and females be vaccinated routinely against oncogenic human papillomavirus (HPV) strains.

The recommendations are outlined in the policy statement HPV Vaccine Recommendations published in the March issue of Pediatrics (2012;129:602-605,http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2011-3865).

Since the last AAP policy statement on HPV vaccination was published in 2007, the Food and Drug Administration added indications for the quadrivalent human papillomavirus vaccine (HPV4 [Gardasil, Merck & Co. Inc.]) to include prevention of warts in adolescent males (2009) and prevention of anal cancers in males and females (2010).

Figure1

Dr. Willoughby

In December 2011, the Centers for Disease Control and Prevention (CDC) recommended that males ages 11 or 12 years routinely receive a three-dose series of quadrivalent HPV vaccine. This recommendation closely parallels the 2006 CDC recommendation for HPV vaccination in females ages 11 or 12 years, using either bivalent or quadrivalent HPV vaccines. There are subtle differences between genders in catch-up strategies for vaccination.

Burden of disease

HPV vaccination has been justified primarily to prevent adult cancers. Each year, HPV types 16 and 18 cause approximately 15,000 cases of cancer in U.S. females (in decreasing order: cervical, vulvar, anal, oropharyngeal and vaginal) and 7,000 cases of cancer in males (in decreasing order: oropharyngeal, anal and penile). Assuming 4 million children in each birth cohort, this is equivalent to one HPV-associated malignancy per 133 females and one per 286 males.

The highest prevalence of HPV infection is found in sexually active adolescents and young adults. HPV vaccination is targeted at the pediatric population before onset of sexual activity to be maximally immunogenic and effective.

Vaccine efficacy

In two large randomized clinical trials (RCTs) in females, the quadrivalent vaccine showed 98.2% per protocol efficacy in preventing precancerous lesions of the cervix or anus. In one large RCT in females, the bivalent vaccine showed 92.9% per protocol efficacy in preventing precancerous lesions of the cervix or anus. In a substudy of high-risk males from one large RCT in males, the quadrivalent HPV vaccine showed 77.5% per protocol efficacy in preventing precancerous lesions of the anus. The quadrivalent HPV vaccine also showed high efficacy in preventing genital warts in males (89.3%) and females (99%).

No large study has evaluated HPV vaccine efficacy against HPV-associated oropharyngeal cancers, which are increasing.

Vaccine safety

The safety of the quadrivalent HPV vaccine was evaluated in two large phase III clinical trials in females, one phase III clinical trial in males and several immunogenicity studies in adolescents.

There also is continued surveillance of potential adverse effects of HPV vaccine through the Vaccine Adverse Event Reporting System as well as real-time surveillance of large health maintenance organization practices via the Vaccine Safety Datalink. After more than 40 million doses administered in the first five years of routine administration in U.S. girls, no discernible, vaccine-specific adverse event, with the exception of rare anaphylaxis to vaccine components, has been detected.

Differences in catch-up vaccination

HPV vaccination can be started at 9 years of age. HPV vaccine (bivalent or quadrivalent) is recommended for females ages 13 through 26 years and quadrivalent for males ages 13 through 21 years who have not initiated or completed the full vaccine series.

HPV vaccine may be given to males 22 through 26 years of age, and should be given to high-risk males through 26 years of age.

Resources

The Academy has developed implementation guidance for the human papillomavirus (HPV) vaccine that covers supply, payment, coding and liability issues, as well as guidance for parents. These documents can be found on Red Book Online at www.aapredbook.org/implementation.

A detailed discussion of quadrivalent HPV vaccine efficacy, safety, cost effectiveness and programmatic considerations for males is available in Morbidity and Mortality Weekly Report, www.cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm?s_cid=mm6050a3_w.

Footnotes

  • Dr. Willoughby is a member of the AAP Committee on Infectious Diseases.

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

AAP News: 33 (3)
AAP News
Vol. 33, Issue 3
1 Mar 2012
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Routine HPV vaccination recommended for all children at 11-12 years
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Routine HPV vaccination recommended for all children at 11-12 years
Rodney E. Willoughby
AAP News Mar 2012, 33 (3) 16; DOI: 10.1542/aapnews.2012333-16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Routine HPV vaccination recommended for all children at 11-12 years
Rodney E. Willoughby
AAP News Mar 2012, 33 (3) 16; DOI: 10.1542/aapnews.2012333-16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
  • Table of Contents

Jump to section

  • Article
    • Burden of disease
    • Vaccine efficacy
    • Vaccine safety
    • Differences in catch-up vaccination
    • Footnotes
  • Info & Metrics
  • Comments

Related Articles

  • This month in Pediatrics
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Strong stance
    AAP releases multiple policies to protect youths from tobacco, nicotine
  • Address causes of climate change to help alleviate effects on children: AAP
  • AAP policy cites harms of e-cigarettes; urges screening
Show more NEWS AND FEATURES

Similar Articles

Subjects

  • Gynecology
    • Gynecology
  • Infectious Diseases
    • Sexually Transmitted Infections
    • Infectious Diseases
    • Vaccine/Immunization
  • AAP NEWS BY DEPARTMENTS
    • AAP Policy
  • Terms of Use
  • Privacy Statement
  • FAQ
  • Contact Us
  • 2021 AAP Journals Catalog
  • Pediatrics
  • Pediatrics in Review
  • Hospital Pediatrics
  • NeoReviews
  • AAP Grand Rounds
  • AAP Career Center
  • shopAAP
  • AAP.org
  • AAP News
  • Visit AAP News on Facebook
  • Follow AAP News on Twitter
American Academy of Pediatrics

© 2021 American Academy of Pediatrics